Early-stage mycosis fungoides (MF) with high-risk features requires a shift toward individualized, symptom-based management rather than a standardized, one-size-fits-all approach. Dermatologists Jade Cury-Martins, MD, PhD, and Maarten H. Vermeer, MD, PhD, suggest that while diagnostic markers for prognosis are evolving, clinicians should currently prioritize patient quality of life, disease location, and symptom burden when choosing between close observation and early systemic treatment.
Why Is Standardizing Treatment for High-Risk MF Difficult?
Standardizing care for early-stage mycosis fungoides remains challenging because high-risk patients are often already managed with more aggressive protocols. According to Cury-Martins, a dermatologist in the Department of Dermatology at the University of São Paulo Medical School, retrospective data—including a large cohort study—show that patients presenting with large-cell transformation or follicular tropic MF typically receive intensified care. Because of this existing clinical bias, conducting a randomized trial that assigns high-risk patients to a “no additional therapy” group presents significant ethical hurdles. Instead of seeking a universal guideline, experts suggest tracking prognostic markers in patients already receiving active treatment to identify which baseline features reliably signal future disease progression.
Mycosis fungoides is an indolent disease. Because of this, survival endpoints take far too long, leading researchers to focus on recurrence, time to next treatment, progression-free survival, and quality of life as more practical trial metrics.
How Can Future Clinical Trials Design Better Outcomes?
To move beyond debate and into clinical guidance, Vermeer, professor and chair of the Department of Dermatology at Leiden University Medical Center, proposes a concrete trial framework. By identifying patients with high-risk markers—such as extensive body surface area, infiltrated plaques, follicular tropism, with or without large-cell transformation—investigators could randomize participants into distinct treatment arms. Rather than waiting for survival data, these trials should prioritize quality of life, recurrence rates, and the time elapsed until the next required treatment. Vermeer emphasizes that these trials must be paired with translational research to investigate the biological drivers behind why specific patients progress while others remain stable.
What Are the Real-World Barriers to Care?
Clinical practice often deviates from trial ideals due to regional limitations and diagnostic inconsistencies. Vermeer notes that the definition of large-cell transformation is not applied uniformly across pathology centers, and a single small biopsy may not represent the entire skin surface. Furthermore, resource availability dictates treatment feasibility. Cury-Martins reports that while interferon is a relatively nontoxic option that can alter the disease course, supply is unreliable, and treatment options in Brazil are more limited than in Europe.
For patients with multiple high-risk features, experts recommend increasing the frequency of clinical follow-ups from every six months to every two or three months to catch progression early.
Frequently Asked Questions
What constitutes a “high-risk” feature in early-stage MF?
High-risk features typically include extensive body surface area, infiltrated plaques, follicular tropism, and, in some cases, large-cell transformation.
Should all high-risk MF patients receive aggressive treatment immediately?
Not necessarily. Experts suggest that treatment should be individualized based on age, occupation, disease location, symptom burden, and the impact the disease has on the patient’s quality of life. Systemic treatment is often reserved for those with high symptom burden when lower-toxicity options exist.
Why is it hard to conduct a randomized trial for this condition?
Ethical concerns arise because clinicians are already treating high-risk patients more aggressively based on retrospective data. Randomizing these patients to a no additional therapy group is often viewed as raising ethical concerns.
Are you a healthcare professional managing cutaneous lymphoma cases? Share your experiences with treatment access or diagnostic challenges in the comments below, or subscribe to our newsletter for the latest updates on oncology research and dermatological advancements.
